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Triple negative breast cancer is often associated with poor prognosis and high 
relapse, which are linked to drug resistance to chemotherapy. Drug resistance 
is a stumbling block in successful cancer treatment and metastatic cancers due 
to chemoresistance accounts for more than 90% of cancer deaths. It is thus 
crucial to develop new strategies to overcome drug resistance and enhance 
efficacy especially in the early setting of TNBC when it is chemo-sensitive 
and controllable. Epigenetic aberrations play an important role in modulating 
resistance and by relying on epigenetics-targeted therapy, these defects could 
be reversed to their normal state and prevented from passing on to future 
generations. In this study, a novel system involving the co-encapsulation of 
vorinostat, a histone deactylase inhibitor, and paclitaxel in mixed micelles 
consisting of vitamin E TPGS and DSPE-PEG2000 was developed to achieve 
maximal therapeutic response by targeting different mechanisms of action. 
Results showed that the TPGS/DSPE-PEG2000 mixed micelles exhibited 
enhanced cellular uptake and stability. In vitro investigations also suggested 
that the micelle system led to improved pharmacokinetics and enhanced 
anticancer activity as the IC50 value decreased from 3.071 in the free drugs 
formulation to 0.520 μg/ml. The cell cycle profile also showed a significant 
and sustained cell cycle arrest in the G2/M phase at 93%.  Inhibition of cell 
migration activity was observed where the wound area only recovered by 2.93 
± 0.01 % compared to 100% in untreated cells. Significant caspase-3 activity 
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1.1 Triple Negative Breast Cancer 
 
Triple negative breast cancer (TNBC) is one of the most difficult breast 
cancers to treat. Although it accounts for about 15% of all invasive breast 
cancers, a large number of breast cancer deaths are associated with TNBC due 
to aggressive tumor behavior and poor clinical outcome. Not expressing any 
receptors for progesterone (PR), estrogen (ER) and the human epidermal 
growth factor 2 (HER2), it is also not responsive to hormonal (i.e. tamoxifen) 
and HER2-targeted therapies (i.e. Herceptin®), which are generally effective 
for most breast cancers (Foulkes, Smith, & Reis-Filho, 2010; Hudis & Gianni, 
2011; Isakoff, 2010; O’Toole et al., 2013; Podo et al., 2010; Shastry & 
Yardley, 2013).  
 
With no specific targets on TNBC, the standard treatment typically involves 
systemic cytotoxic chemotherapy, surgery or radiation. Combinatory 
chemotherapy before surgery is frequently utilized in a complex disease such 
as TNBC where it consists of heterogeneous groups of tumors. It is believed 
that administration of two or more anticancer agents that target different 
mechanisms of action could maximize the therapeutic effect and reduce drug 
resistance (Greco & Vicent, 2009; Pinto, Moreira, & Simões, 2011). Patients 
are responsive to taxanes- and anthracyclines-based treatment regimes; 
according to neoadjuvant studies, favorable prognosis is associated with 
patients showing a pathological complete response (pCR). However, despite 
success in the early setting of TNBC, patients still have a greater risk of 
relapse and developing visceral metastases with worse survival rates after 
treatment than non-TNBC patients (Arnedos, Bihan, Delaloge, & Andre, 
2012; Isakoff, 2010). It has been suggested that a small subpopulation of 
resistant cells present in TNBC called cancer stem cells (CSCs) might play a 
role in the less favorable outcome encountered in TNBC patients.  
 
The poor prognosis and high risk of relapse pose to be a clinical challenge for 
TNBC; hence, it is crucial to develop new strategies to overcome drug 
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resistance and to enhance efficacy especially in the early setting when TNBC 
is chemo-sensitive and controllable.  
 
1.2 Therapeutic Resistance  
 
Drug resistance to chemotherapy is a stumbling block in successful cancer 
treatment that affects the survival rates of patients where metastatic cancers 
due to chemoresistance accounts for more than 90% of cancer deaths 
(Abdullah & Chow, 2013). Therapeutic resistance can arise from tumor cells 
that are intrinsically resistant as well those that have acquired resistance 
during treatment.  
 
According to the hierarchical model of cancer progression, there exists a small 
subpopulation of cells within the tumor called the cancer stem cells (CSCs) 
that are intrinsically refractory to treatment and that explain the relapse of 
cancer and metastasis. Depending on the type of cancer involved, the 
proportion of CSCs accounts for 0.1% to 30% in tumors. Being capable of 
self-renewal, CSCs that survive after treatment develop new and more 
malignant tumors, which lead to the development of acquired drug-resistant 
cancer cells and also poor prognosis (Basile & Aplin, 2012; Buchstaller, 
Quintana, & Morrison, 2008; Dean, Fojo, & Bates, 2005; Vinogradov & Wei, 
2012). In solid tumors such as breast tumors, the expression of the phenotype 
CD44+/CD24- is characteristic of CSCs. MDA-MB-231, a TNBC cell type, 
shows a high percentage of the CD44+/CD24- biomarker which is indicative of 
CSCs.  
 
The main mechanism for this phenomenon involves the expression of drug 
efflux transporter protein called the P-glycoprotein (P-gp). P-gp is a 
phosphoglycoprotein. It is also known as the ATP-binding cassette sub family 
B member 1 (ABCB1) transporter protein and contains two ATP-binding 
cassette domains. The presence of hydrophobic drugs would activate the 
binding of the drugs to the ATP-binding cassette domains that result in the 
hydrolysis of ATP. This subsequently leads to a change in the conformation of 
3 
P-glycoprotein and enhances the efflux of the drugs from the cells, which then 
prevents drug-induced apoptosis and impairs the normal functioning of the 
cell cycle checkpoints (Fojo & Bates, 2003; Gottesman, 2002; Kavallaris, 
2010).  
 
The high relapse rate and the tumor heterogeneity encountered in TNBC 
suggest that cancer stem cells may be accountable for therapeutic resistance. 
Hence, novel treatments have to be developed to prevent the formation of 
drug-resistant cells as well as to decrease their resistance to anticancer agents.  
 
1.3 Cancer and Epigenetics 
 
Cancer was believed to be caused by genetic changes alone but there are 
increasing evidence to show that epigenetic events play an important role in 
modulating cancer progression and resistance. Epigenetic events are caused by 
chromatin changes that in turn modify gene expression without any DNA 
sequence alterations. Unlike genetic defects, epigenetic aberrations could be 
reversed to their normal state by targeting epigenetic enzymes responsible for 
the abnormalities, which makes them attractive targets for anticancer 
treatment as well as countering therapeutic resistance.  Epigenetic changes are 
heritable and affect the global state of the cells; thus, reversing cancer 
phenotypes via epigenetic-targeted therapy could prevent the epigenetic errors 
from being passed on to future generations (Balch & Nephew, 2013; Baylin, 
2011; Hoey, 2010; Kristensen, Nielsen, & Hansen, 2009; Pandian & 
Sugiyama, 2012; Perego, Zuco, Gatti, & Zunino, 2012; Rodríguez-Paredes & 
Esteller, 2011; Wilting & Dannenberg, 2012).   
 
Epigenetic aberrations are mainly modulated by DNA methylation and histone 
modifications in an interdependent manner. DNA methylation occurs at the 
CpG islands or the regions in the genome that contains cytosine and guanine, 
and is located at about 70% of the gene promoter sites (Dworkin, Huang, & 
Toland, 2009). Hypermethylation of DNA sequences leads to the repression of 
tumor suppressor genes due to the steric hindrance encountered by 
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transcription complexes when accessing the promoter in a closed chromatin 
configuration. The nucleosome constitutes the fundamental unit of the 
chromatin and consists of DNA wrapped around eight histones. Post-
translational modification of the histones, which include acetylation, 
methylation, and phosphorylation, affects the chromatin configuration and 
alter gene expression. In histone acetylation, the equilibrium state is mediated 
by the counter activities of histone acetyltransferases (HATs) and histone 
deactylases (HDACs). HATs are transcription activators that transfer an acetyl 
group to the lysine residue of histones while conversely; HDACs act to 
counter the acetylation activity by removing the acetyl groups. However, 
hypoacetylation results in a closed chromatin configuration and silenced gene 
expression. When the genes methylated or histones modified are associated 
with cell cycle regulation, apoptosis, DNA repair and cell adhesion, 
carcinogenesis occurs (Cortez & Jones, 2008; Ellis, Atadja, & Johnstone, 
2009; Jones & Baylin, 2002; Jovanovic, Rønneberg, Tost, & Kristensen, 2010; 
Zeller & Brown, 2010; Zhou et al., 2009).  
 
1.3.1 Histone Deactylases (HDACs) 
 
There are a total of eighteen histone deacetylases (HDACs) in humans and 
they fall under three main classes depending on their homology to yeast 
proteins. Class I HDACs are found mainly residing within the nucleus and 
contribute to the survival and differentiation of the cells; they include HDAC 
1, 2, 3 and 8. Class II HDACs can be found in the nucleus or the cytoplasm 
and perform roles that are specific to the tissue; they include HDAC 4, 5, 7 
and 9. HDAC 6 and 10 that contain two catalytic sites belong to the subclass 
Class IIa. HDAC 11 is uniquely classified under Class IIb as it has conserved 
residues identified in the catalytic sites that are shared by both Class I and II. 
These HDAC proteins identified above contain zinc in their catalytic core 
regions and also target non-histone proteins that play a role in regulating cell 
differentiation and apoptosis. Another class of HDACs known as Class III or 
the sirtuin family does not have non-histone substrates. HDACs catalyse the 
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removal of acetyl groups from lysine residues at the NH2-terminal of histones 
and also interact with non-histone substrates such as transcription factors, co-
activators and co-repressors (Dokmanovic, Clarke, & Marks, 2007; Frew, 
Johnstone, & Bolden, 2009; P a Marks & Xu, 2009; New, Olzscha, & La 
Thangue, 2012).   
 
1.4 Epigenetics-targeted therapy using inhibitors of HDACs  
 
HDACs enzymes that have impaired regulation could change gene expression 
levels and lead to abnormal cell growth (Carew, Giles, & Nawrocki, 2008; 
Cortez & Jones, 2008; Grant, Easley, & Kirkpatrick, 2007; Kaiser, 2010; Paul 
a Marks & Breslow, 2007). Thus, using inhibitors of histone deactylase 
(HDACi) that facilitate the accumulation of acetylated histone and non-histone 
proteins to induce cell cycle arrest and apoptosis would be a promising target 
in cancer therapy.  
 
Suberoylanilide hydroxamic acid (S), known commercially as vorinostat 
(Zolinza), is an FDA approved HDACi drug for the treatment of cutaneous T-
cell lymphoma. It targets multiple agents from inhibiting HDACs of Class I 
and II at nanomolar concentrations to non-histone proteins involved in gene 
expression regulation; this accounts for its efficacy as an anticancer agent as 
cancers are usually caused by multiple epigenetic aberrations. Some examples 
of the non-histone substrates include transcription factor complexes, 
retinoblastoma protein in cell proliferation, heat shock protein i.e. HSP-90 in 
protein stability, α-tubulin in cell motility and hypoxia-inducible factor-1α in 
angiogenesis. The mechanism of action by vorinostat is complex and not well 
understood but it is believed to induce cell growth arrest and cell death via the 
intrinsic and extrinsic apoptotic pathway, autophagy as well as reactive 
oxygen species-mediated apoptosis (Dokmanovic et al., 2007; Ververis, 
Hiong, Karagiannis, & Licciardi, 2013; Xu, Parmigiani, & Marks, 2007). In 
particular, vorinostat could lead to retinoblastoma-mediated cell cycle arrest in 
phase G1/S by targeting cyclin-dependent kinase inhibitor p21 encoded by 
CDKN2A that is upregulated in TNBC (Paul a Marks & Breslow, 2007).  
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Phase I clinical trials with vorinostat as a monotherapy treatment were 
evaluated in patients with hematologic and solid cancers administered 
intravenously and orally. Minimal anticancer activity was reported and it is 
suggested that vorinostat is not effective alone and has to be used in 
combination chemotherapy to achieve greater therapeutic effect (Prince, 
Bishton, & Harrison, 2009). There has been increasing interest in using 
vorinostat in TNBC where it has been reported to inhibit brain metastatic 
colonization and induce the breakage of DNA strands (Palmieri et al., 2009). It 
has also been suggested to sensitize the TNBC cells to certain cisplatin and 
PARP inhibitor treatment (Bhalla et al., 2012). Thus, it would be interesting to 
further explore the therapeutic effects of vorinostat in TNBC with another 
chemotherapy regime such as taxanes.  
 
1.5 Combination Chemotherapy with Paclitaxel 
 
Taxanes or microtubule inhibitors are recognized as effective anticancer drugs 
in the treatment of breast cancers and TNBC. Clinical studies involving ER-
negative subtypes have demonstrated that pCR was higher when taxanes were 
added (Isakoff, 2010), thus emphasizing the importance of taxanes in the 
treatment of ER-negative breast cancers.  
 
One example of drugs in the class of taxanes is paclitaxel (P), or Taxol® as it 
is commercially known, which was approved by FDA in 1992 for the 
treatment of advanced ovarian cancer and later in 1994 for metastatic breast 
cancer. Paclitaxel is a semi-synthetic drug that acts on microtubules. 
Microtubules form a part of the cytoskeleton and are located at the centrosome 
in the cytoplasm. The fundamental subunits that account for the structure 
consist of the α-tubulin and β-tubulin monomers. The polymerization and 
depolymerization of the microtubules via the addition and removal of these 
tubulin monomers play a role in various important cellular activities such as 
cell movement and mitosis. Paclitaxel stabilizes microtubules by binding to 
the β-tubulin subunit and thereby minimizes depolymerization. Three possible 
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consequences can arise in the presence of paclitaxel: cell death at G1 phase, 
cell cycle arrest in the G2/M phase that subsequently induces apoptosis or 
mitotic slippage (Gascoigne & Taylor, 2009; Horwitz et al., 1986; Kavallaris, 
2010; McGrogan, Gilmartin, Carney, & McCann, 2008).  
 
Docetaxel is another member of the taxane family that works on inhibiting 
microtubule division. Even though it is more potent and more water-soluble 
than paclitaxel, docetaxel is more susceptible to drug resistance and there are 
also less side effects associated with paclitaxel (Leung, Tannock, Oza, 
Puodziunas, & Dranitsaris, 2010). Furthermore, the combination of paclitaxel 
and vorinostat and another drug of interest as chemotherapy treatment is more 
often encountered in literature (Owonikoko et al., 2010; Ramalingam et al., 
2010; Ramaswamy et al., 2012; Siegel et al., 2009). No specific studies on the 
combinatory treatment of docetaxel and a HDAC inhibitor were found; 
docetaxel was more frequently associated with platinum-based drugs such as 
cisplatin and carboplatin in clinical studies (Kashima, Aoki, Yahata, & 
Tanaka, 2005; Pentheroudakis et al., 2008; Takekida et al., 2010; Vasey et al., 
1999). It was also reported that paclitaxel was more effective in breast cancer 
models, in particular MDA-MB-231 cells, whereas docetaxel was more 
effective in solid malignancies such as non-small cell lung cancer (Izbicka, 
Campos, Carrizales, & Tolcher, 2005). Thus, paclitaxel is selected as the 
taxane of choice in this study due to its higher efficacy in breast cancer 
models, which would have more impact in the field of triple negative breast 
cancer.   
 
Treatment combining epigenetics and anti-mitotic targeted therapies could 
improve the therapeutic response of single chemotherapy as using epigenetic 
modulators such as vorinostat could prevent the formation of drug-resistant 
colonies and reduce the resistance to anticancer agents (Bots & Johnstone, 
2009; Greco & Vicent, 2009; Thurn, Thomas, Moore, & Munster, 2011). 
Also, since both agents target different pathways of action, enhanced 
antineoplastic activity could be achieved. Preclinical studies in ovarian cancer 
have shown the synergism of the two drugs where enhanced cytotoxicity and 
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apoptosis were observed but no studies on the two drugs could be found in 
triple negative breast cancer (Angelucci et al., 2010; Cooper et al., 2007; 
Dietrich et al., 2010; Modesitt & Parsons, 2010).  
 
1.6 Challenges in Conventional Chemotherapy 
 
Even though concurrent chemotherapy would show enhanced anti-cancer 
effects, its effectiveness is often hindered by the poor solubility of the drugs 
and their toxicity levels which are not well-tolerated by the patients in clinical 
trials.  
 
Both paclitaxel and vorinostat are highly hydrophobic compounds. Hence, 
paclitaxel is usually formulated with alcohol and Cremophor® EL in Taxol® 
dosage form to improve bioavailability but hypersensitivity reactions 
associated with the solvents can often result (Pinto et al., 2011). The side 
effects associated include myelosuppression, alopecia, gastrointestinal 
symptoms and also peripheral neuropathy. Furthermore, it is impractical to use 
the intravenous formulation of vorinostat on a routine basis where it involves 
suspending vorinostat in sodium hydroxide at a high pH of 11.2 in a phase I 
clinical trial (Cai et al.). Some common side effects encountered in vorinostat 
usage include anemia, thrombocytopenia, fatigue and diarrhea. Moreover, 
different drug molecules with dissimilar pharmacokinetics and biodistribution 
could lead to more serious side effects when combined. Thus, to fully 
capitalize on the benefits of combination chemotherapy, a drug delivery 
system free of organic solvents that can improve pharmacokinetics to 




Nanocarrier drug delivery systems offer a solution to the problems 
encountered by conventional chemotherapy. By encapsulating the 
hydrophobic drugs in the core of the nanocarrier, the drugs can be delivered to 
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the tumor site with reduced toxicities and at a controlled rate without 
significant loss of their activity (Hu, Aryal, & Zhang, 2010).  
 
One of the advantages of using nanoparticulate system is the ability to control 
the size and surface characteristics of the nanocarriers. Nanocarriers with a 
size too small would risk being leaked into the blood capillaries whereas a size 
that is too large would be easily recognized by the macrophages and removed 
by the reticuloendothelial system (RES). A suitable size of up to 100 nm 
would satisfy both criteria. A hydrophilic surface is required for the 
nanocarriers to be protected from opsonisation and to escape clearance from 
the RES for a longer circulatory time in the blood system. This can be 
achieved by either coating the surface with a hydrophilic layer of 
poly(ethylene) glycol (PEG) or synthesizing the nanocarriers with amphiphilic 
polymers consisting of both hydrophobic and hydrophilic chains. The unique 
feature of tumor tissues also enables drug carriers to accumulate passively at 
the tumor sites by the enhanced permeability and retention effect (EPR). 
Proliferating tumor tissues stimulate the production of new vessels to supply 
them with more oxygen and nutrients, which are usually highly disorganized 
with enlarged pores. The leaky vasculature and the lack of lymphatic drainage 
contribute to the preferential accumulation of drug carriers in tumor tissues 
(Alexis, Pridgen, Langer, & Farokhzad, 2010; Banerjee & Sengupta, 2011; 
Cho, Wang, Nie, Chen, & Shin, 2008). Nanocarriers are also believed to be 
able to mediate the development of chemoresistance by evading recognition 
by the P-gp efflux pump through internalization by endocytosis due to their 
small size. Free drug molecules are immediately pumped out of cells by the P-
gp protein when they enter by passive diffusion. On the other hand, 
nanocarriers are being engulfed by the plasma membrane and transported to 
the tumor site of action via endosomal vesicles, which can partially bypass the 
P-gp efflux pumps. The drug molecules are then released at sites far away 
from the drug efflux pumps and thus could interact with the tumor cells more 
efficiently (Dong & Mumper, 2010; Hu & Zhang, 2009).    
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Self-assembling polymeric micelles constructed from amphiphilic block co-
polymers have gained increasing interest as nanocarriers due to their attractive 
properties. Other than being biodegradable, their small size ranging from 10 to 
100 nm enables them to penetrate deeply into the tumors via the EPR effect 
and they can successfully solubilize highly hydrophobic compounds 
(Chandran, Katragadda, Teng, & Tan, 2010; Ebrahim Attia et al., 2011; Gill, 
Kaddoumi, & Nazzal, 2012; Katragadda, Teng, Rayaprolu, Chandran, & Tan, 
2011; Mu, Elbayoumi, & Torchilin, 2005; Tyrrell, Shen, & Radosz, 2010).  !
1.8 Problem Statement  
 
In this study, a novel system involving the co-encapsulation of paclitaxel and 
vorinostat in the core of the micelles, which are made up of D-α-tocopheryl 
polyethylene glycol 1000 succinate (vitamin E TPGS or TPGS) and 1,2-
distearoyl-sn-glycero-3-phosphoethanolamine polyethylene glycol 2000 
(DSPE-PEG2000) was developed. TPGS is the hydrophilic moiety of vitamin 
E, which is used in a wide range of applications as an emulsifier, additive and 
also an agent for inhibiting P-gp-mediated multidrug resistance (Mi, Liu, & 
Feng, 2011; Mi, Zhao, & Feng, 2012; Muthu, Kulkarni, Liu, & Feng, 2012; 
Zhang, Tan, & Feng, 2012). However, it is limited by its high critical micelle 
concentration (CMC) of 0.2 mg/ml that causes the micelles to dissociate easily 
especially under high dilution (Kim, Shi, Kim, Park, & Cheng, 2010; Kita & 
Dittrich, 2011). Hence, a more hydrophobic surfactant such as DSPE-
PEG2000 is used together with TPGS to form a mixed micelle for enhanced 
micelle stability.  
 
MDA-MB-231 cells, a cell-line with a high percentage of CD44+/CD24- (> 
30%), were used as the in vitro model of TNBC to investigate the biological 
effects of the dual drug encapsulated micelles compared with the free drugs 
formulations (Sheridan et al., 2006). The objective is to prove the 
effectiveness of nanocarriers in inducing enhanced anti-cancer effects where 











Figure 1: Schematic illustration of the formulation of paclitaxel- and 
vorinostat-loaded DSPE-PEG2000/TPGS mixed micelles !
2. MATERIALS AND METHODS 
2.1 Materials 
 
Vitamin E TPGS (D-α-tocopheryl polyethylene glycol 1000 succinate, 
C33O5H54(CH2CH2O)23) was purchased from Eastman Chemical Company, 
USA. Paclitaxel (anhydrous, 99.5%) and vorinostat (anhydrous, 99.7%) were 
bought from Tocris Bioscience, USA. DSPE-PEG2000 (1,2-distearoyl-sn-
glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-2000] 
(ammonium salt)) was purchased from Avanti Polar Lipids. Phosphate 
buffered saline (PBS), penicillin-streptomycin solution, trypsin-EDTA 
solution, coumarin 6, 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-
tetrazolium bromide (MTT), ribonuclease A (Rnase A) from bovine pancreas, 
pyrene, propidium iodide (PI), dimethyl sulfoxide (DMSO), chloroform, 
dichloromethane (DCM), tetrahydrofuran (THF), paraformaldehyde (PFA), 
acetonitrile (ACN) were from Sigma-Aldrich (St. Louise, MO, USA). Ethanol 
was from VWR Singapore Pte Ltd, Alexa Fluor® 647 Phalloidin, ProLong® 
Gold Anti-fade reagent with DAPI were from Invitrogen. RPMI-1640 was 
bought from Thermo Scientific HyClone (South Logan, USA). All chemicals 
used in this study were of HPLC grade. Ultra-pure water was produced by the 
Milli-Q Plus System (Millipore Corporation, Bedford, USA). MDA-MB-231 









breast cancer cells were provided by American Type Culture Collection 
(ATCC).  
 
2.2 Formulation of paclitaxel- and vorinostat-loaded DSPE-
PEG2000/TPGS micelles 
 
The paclitaxel- and vorinostat-loaded DSPE-PEG2000/TPGS or coumarin 6 
(C6)-loaded micelles were fabricated by the solvent evaporation method. 1 mg 
of paclitaxel and vorinostat (1 : 1 molar ratio) and 30 mg of TPGS and DSPE-
PEG2000 (1 : 1 weight ratio) were dissolved in chloroform which were then 
evaporated using the rotary vacuum evaporator at 35 °C until a thin film of 
drug-dispersed TPGS was formed. The film was further dried in vacuum 
overnight and suspended in 10 ml of 1 × PBS buffer before being incubated in 
an orbital water bath at 37 °C for 30 minutes followed by 15 minutes of 
sonication. A 0.22-μm filter was used to separate the excess non-incorporated 
drug from the suspension before characterization.  
 
2.3 Characterization of micelles 
2.3.1 Micelle shape, size and size distribution and surface charge 
 
Micelle shape was visualized using the field emission transmission electron 
microscope (FETEM, JEM-2200FS, JEOL, Japan). The suspension was 
dropped on the surface of a copper grid with a carbon film and dried at room 
temperature. Micelle size and size distribution as well as the zeta potential 
were measured by dynamic light scattering (DLS) (Nano ZS, Malvern 
Instruments, Malvern, UK). The suspension was diluted with ultra-pure water 
and sonicated before measurement. 
 
2.3.2 Drug encapsulation efficiency 
 
The amount of paclitaxel or vorinostat encapsulated in the micelles was 
measured using high performance liquid chromatography (HPLC, Agilent 
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LC1100, Agilent, Tokyo, Japan) in a reversed phase column (Eclipse XDB-
C18, 4.6 × 250 mm, 5 μm). 1 ml of micelles were freeze-dried and dissolved 
in 1 ml of DCM followed by the evaporation of DCM overnight. The resulting 
sample was dispersed in 1 ml of mobile phase consisting of ACN and water 
(50 : 50 v/v) and then filtered with a 0.45-μm syringe filter before being 
transferred into a HPLC vial. The flow rate of the mobile phase was set at 1 
ml/min and the column effluent was detected with an UV/visible detector at 
230 nm and 240 nm for paclitaxel and vorinostat respectively. The drug 
encapsulation efficiency is defined as the ratio of the amount of drug 
encapsulated in the micelles to that added during the formulation process.  
 
2.3.3 Critical micelle concentration (CMC)  
 
The critical micelle concentration of the micelles was estimated using the 
pyrene as the fluorescent probe (Sawant & Torchilin, 2010). 50 μl of 1.8 × 10-4 
M solution of pyrene in DCM was added to varying concentrations of DSPE-
PEG2000/TPGS in DCM ranging from 0.001 mg/ml to 0.6 mg/ml. A pyrene 
film was formed after evaporating DCM for 24 hours followed by the addition 
of 15 ml UP water to obtain a final pyrene concentration of 6.0 × 10-7 M. The 
suspension was incubated in an orbital water bath at 37 °C for 24 hours to 
reach equilibrium before being filtered through a 0.2-μm syringe filter to 
remove the free pyrene. It was then transferred to a 96-well black microplate 
where the fluorescence intensities were measured using the microplate reader 
(Genios, Tecan, Männedorf, Switzerland). The excitation wavelength was 
scanned from 306 nm to 346 nm and the emission wavelength at 373 nm. 
 
2.4 Drug release profile 
 
The dialysis bag diffusion technique was used to study the in vitro drug 
release profile of paclitaxel and vorinostat. 4 ml of suspension was placed in a 
dialysis bag (Spectra/Por® Dialysis Membrane, MWCO 10,000Da) and 
immersed into 20 ml of 1 × PBS buffer containing 0.1% w/v Tween 80 at 
14 
37 °C with constant agitation. The incubation medium outside the dialysis bag 
was collected at designated time intervals and replaced with fresh incubation 
medium. The collected incubation medium containing the released drug was 
then freeze-dried and dissolved in DCM. The amount of paclitaxel or 
vorinostat was determined using HPLC in the procedure mentioned in 2.3.3. 
 
2.5 in vitro studies 
2.5.1 Cell cultures 
 
MDA-MB-231 cancer cells used in the cell studies were cultured using RPMI-
1640 with 10% FBS and 1% penicillin-streptomycin. The cells were incubated 
with 5% CO2 at 37 °C in a humidified incubator. Before the in vitro 
experiments, the cells were pre-cultured until confluence was reached.  
 
2.5.2 Cellular uptake 
 
Quantitative cellular uptake  
 
MDA-MB-231 cells were seeded in the 96-well black plates at 5,000 
cells/well. After 24 hours, the medium were discarded and the cells in the 
sample wells were incubated for 2 hours in the media containing C6-loaded 
micelles at a concentration of 2.5, 0.25 and 0.025 μg/ml as chosen from 
previous studies by the research group whereas the cells in the control wells 
were incubated in 0.5% Triton X-100 in 0.2 N NaOH solution containing the 
micelle suspensions. After incubation, the micelles suspension from the 
sample wells was removed and washed three times with PBS followed by the 
addition of 50 μl of 0.5% Triton X-100 in 0.2 N NaOH solution to the cells. 
The fluorescence intensities from the C6-loaded micelles were then measured 
using the microplate reader (Genios, Tecan, Männedorf, Switzerland) where 
the excitation wavelength was set at 430 nm and the emission wavelength at 
485 nm. Cellular uptake efficiency was then calculated to be the percentage of 
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the fluorescence intensity of the cells in the sample wells to that in the control 
wells.   
 
Qualitative cellular uptake 
 
MDA-MB-231 cells were cultivated in the 8-well chambered coverglass 
system (LAB-TEK®, Nagle Nunc International, Rochester, NY) till 70% 
confluence. The C6 or C6-loaded micelles dispersed in the cell medium at a 
concentration of 25 μg/ml were added into the wells and incubated at 37 °C 
for 2 hours.  The cells were washed three times with PBS and fixed by 4% 
PFA for 15 minutes at 4 °C. They were further washed and incubated with 0.2% 
(v/v) Triton X-100 in PBS for 10 minutes at 20 °C to lyse the cells and 
incubated with Alexa Fluor® 647 Phalloidin at 20 °C for 30 minutes in the 
dark to stain the f-actin before being added with ProLong® Gold Anti-fade 
reagent with DAPI to stain the nuclei. It was then observed under the confocal 
laser-scanning microscope (CLSM, Olympus Fluoview FV1000, Japan).  
 
2.5.3 MTT cell viability 
 
MDA-MB-231 cells were incubated in the 96-well clear plates (Nunc, 
Roskilde, Denmark) with a cell density of 5,000 cells/well. After seeding 
overnight to allow for attachment, the medium was discarded and the cells 
were incubated for 24 hours in the medium containing (1) P, (2) S, (3) P + S, 
(4) Pmic, (5) Smic, (6) Pmic + Smic, (7) (P + S)mic or (8) blank micelles at the 
equivalent drug concentration of 25, 2.5, 0.25 and 0.025 μg/ml as chosen from 
previous studies by the research group. After incubation, the cultured cells 
were assayed for cell viability with MTT. The wells were first washed twice 
with PBS and then incubated with 0.5 mg/ml MTT suspended in culture 
medium for 3 hours at 37 °C in the dark. The culture medium was later 
removed and the purple crystals were dissolved in DMSO. The fluorescence 
intensities of the cells were then measured using the microplate reader (Genios, 
Tecan, Männedorf, Switzerland) where the absorbance wavelength was set at 
570 nm and the background wavelength at 660 nm. Cell viability was then 
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calculated to be the percentage of the fluorescence intensity of the cells 
incubated with the respective formulation to that incubated with the culture 
medium.   
 
2.5.4 Cell cycle analysis  
 
MDA-MB-231 cells were incubated in the 6-well plates (Nunc, Roskilde, 
Denmark) until confluent. The medium was later discarded and the cells were 
incubated for 24 hours in the media containing (1) P, (2) S, (3) P + S  (4) Pmic, 
(5) Smic, (6) Pmic + Smic, (7) (P + S)mic or (8) blank micelles at the equivalent 
drug concentration of 0.250 μg/ml where not much cell death is encountered 
according to cell viability studies. After incubation, both floating cells and 
adherent cells were collected and transferred to 15-ml centrifuge tubes where 
they were re-suspended at 1×106 cells/ml of cold PBS. The suspension was 
then added drop-wise to 9 ml of ice cold 70% ethanol and incubated at 4 °C 
for overnight to allow fixation. After fixation, the cells were washed with cold 
PBS and re-suspended in 500 μl of Rnase A in PI/0.1% (v/v) Triton X-100 
solution. After incubation at room temperature for 30 minutes, the tubes were 
stored at 4 °C in the dark before data acquisition in flow cytometer BD 
LSRFortessa™.  
 
2.5.5 Caspase-3 activity  
 
MDA-MB-231 cells were incubated in the 96-well black plates (Nunc, 
Roskilde, Denmark) with a cell density of 5,000 cells/well. After seeding 
overnight to allow for attachment, the medium was discarded and the cells 
were incubated for 24 hours in the media containing (1) P, (2) S, (3) P + S  (4) 
Pmic, (5) Smic, (6) Pmic + Smic, (7) (P + S)mic or (8) blank micelles at the 
equivalent drug concentration of 0.250 μg/ml. After incubation, the cultured 
cells were assayed for caspase-3 activity using the Biovision Caspase-
3/CPP32 fluorometric assay kit.  The wells were first incubated with cell lysis 
buffer for 10 minutes in ice. Reaction buffer containing DTT and DEVD-AFC 
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substrate was added and left to incubate for 2 hours at 37 °C. The fluorescence 
intensities of the cells were then measured using the microplate reader (Genios, 
Tecan, Männedorf, Switzerland) where the excitation filter was set at 400 nm 
and the emission filter at 505 nm. The fold-increase in caspase-3 activity in 
the indicated formulations was determined by comparing with the control.  
 
2.5.6 Scratch wound-healing assay 
 
MDA-MB-231 cells were incubated in the 48-well plates (Nunc, Roskilde, 
Denmark) coated with 0.01% gelatin until confluent. A vertical wound mark 
was created by scratching the cell monolayer with a 200 μl sterile pipette tip 
(Sarfstein, Bruchim, Fishman, & Werner, 2011) (Rodriguez, Wu, & Guan, 
2005). The wells were then washed twice with PBS to remove debris and 
detached cells. The cells were incubated in the media containing (1) P, (2) S, 
(3) P + S  (4) Pmic, (5) Smic, (6) Pmic + Smic, (7) (P + S)mic or (8) blank micelles at 
the equivalent low drug concentration of 0.01 μg/ml to prevent apoptosis at 
37°C and monitored at the start of the experiment and after 24 hours using a 
phase-lapse inverted microscope. The images acquired were analyzed using 
the software ImageJ to study the inhibition of cell migration by measuring the 
open wound area at each time point.  
 
2.6 Statistical analysis  
 
The experimental data is expressed as mean ± standard error of mean. 
Statistical analysis was first performed using the ANOVA one-factor test 





3. RESULTS AND DISCUSSIONS 
3.1 Characterization of micelles 
3.1.1 Micelle shape, size and size distribution and surface charge 
 
A weight ratio of DSPE-PEG2000 : TPGS = 1 : 1 was used for the 
experiments that was the recommended value (Sawant & Torchilin, 2010). 
The drug ratio of P : S was optimized based on maximum drug loading 
capacity in previous experiments that were not reported and determined to be 
a weight ratio of 1 : 1. Literature has reported that a maximum cut-off size of 
100 nm be required for the nanocarriers. This is to allow passive accumulation 
in the leaky tumor tissues where the gap between endothelial cells is estimated 
to be between 100 and 600 nm (Cho et al., 2008).  
 
Table 1 shows that the dual encapsulation of P and S yielded a particle size of 
about 12 nm for both TPGS and DSPE-PEG2000/TPGS micelles, which is 
below the cut-off size.  There were no significant differences in the micelle 
size between the two formulations when a different polymer ratio was used. 
The overall micelle size is influenced by the micelle aggregation number, 
which determines how the amphiphilic chains are packed into micelles. This is 
dependent on various factors such as the molecular weight as well as the 
length and proportion of the hydrophobic and hydrophilic segment (Croy & 
Kwon, 2006). The same micelle aggregation number could explain their same 
size where more studies could be done on fluorescence quenching to 
determine the aggregation number. As TPGS (MW 1513) and DSPE-
PEG2000 (MW 2806) have different molecular weights, the relative 
proportion and length of the hydrophobic and hydrophilic block may be more 
important in determining the aggregation number where more experiments 
could be conducted as well.      
 
The size distribution of the two formulations was also uniform with a PDI of 
below 0.300. No size-exclusion procedure was required to attain this narrow 
size distribution, which is also an advantage of the micelle preparation. The 
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surfactant concentration or the critical micelle concentration also restricts the 
thermodynamically stable size. In particular, the formulation of DSPE-
PEG2000/TPGS micelles had a favorable PDI of 0.194. This was below the 
pharmaceutical standard of 0.200, which ensures homogeneity and optimized 
stability of the formulation.   
 
The magnitude of the zeta potential is an indicator of the stability of the 
micelles. Both DSPE-PEG2000/TPGS and TPGS micelles had a high negative 
charge of -22.5 ± 2.9 and -13.3 ± 0.1 mV respectively. This suggested that 
strong repulsive forces exist between the particles that lead to a lower 
tendency for the micelles to aggregate and thus form a highly stable solution. 
Results also indicated that DSPE-PEG2000 micelles exhibited a more negative 
surface charge, which is due to the presence of a negatively charged phosphate 
group.  
 
Table 1: Size distribution and zeta potential of dual drug loaded DSPE-












Figure 2: Transmission electron microscopy image of paclitaxel- and 
vorinostat-loaded DSPE-PEG2000/TPGS mixed micelles 
 
Micelles Formulation Size (nm) PDI Zeta Potential (mV) 
DSPE-PEG2000/TPGS 11.32 ± 0.18 0.194 ± 0.033 -22.5 ± 2.9 
TPGS 11.76 ± 0.48 0.271 ± 0.030 -13.3 ± 0.1 
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The shape of the DSPE-PEG2000/TPGS micelles was visualized using 
FETEM and Figure 2 shows that the micelles were spherical. The size was 
approximated to be about 15 nm which was slightly larger than that measured 
by DLS.  
 
3.1.2 Drug encapsulation efficiency 
 
Drug encapsulation efficiency (EE) is an important parameter in drug delivery 
system, as higher encapsulation efficiencies would mean that an enhanced 
therapeutic effect with reduced side effects could be achieved.  It was reported 
that addition of fatty acids salts to amphiphilic block co-polymers to form 
mixed micelles resulted in higher drug loading. From Table 2, it was observed 
the mixed micelles of DSPE-PEG2000/TPGS yielded an encapsulation 
efficiency of 97.6 ± 0.3 % and 99.5 ± 2.7 % for paclitaxel and vorinostat 
respectively, which is higher than single-component TPGS micelles of 79.9 ± 
5.3 % and 88.4 ± 3.6 %. The higher encapsulation efficiency of the mixed 
micelles could be attributed to a more hydrophobic core that enabled more 
poorly soluble drug molecules to be loaded due to the addition of a highly 
hydrophobic DSPE-PEG2000.  
 
Table 2: Encapsulation efficiency and drug load of dual drug loaded DSPE-







Micelles Formulation EE (%) Drug Load (µg/mg) P S P S 
DSPE-PEG2000/TPGS 97.6 ± 0.3 99.5 ± 2.7 3.12 ± 0.01 3.18 ± 0.09 
TPGS 79.9 ± 5.3 88.4 ± 3.6 2.63 ± 0.18 2.91 ± 0.12 
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3.1.3 Critical micelle concentration (CMC) 
 
Critical micelle concentration is the concentration when amphiphilic block co-
polymer units self-assemble to form micelles. At this state of minimum 
energy, the hydrophobic elements orient away from the aqueous environment 
to form a stabilized micelle core with the hydrophilic elements pointing 
outwards. At concentrations above the CMC, micelles remain in this state 
without dissociating. Thus, it is desirable to have a low CMC value to prevent 
the micelles from dissociating upon dilution in the circulatory system after 
intravenous administration. Using pyrene as the fluorescent probe for 
determination of CMC is one of the most accurate methods. Below the CMC, 
pyrene is solubilized in the solvent to a small extent and has relatively low 
fluorescence intensity. However, as the concentration of DSPE-
PEG2000/TPGS increases, more hydrophobic cores are available to solubilize 
pyrene leading to an increase in fluorescence intensity. The change in slope of 
the fluorescent intensity represents the formation of micelles and the 
intersection is the CMC value. 
 
Pyrene was dissolved in DSPE-PEG2000/TPGS concentrations varying from 
0.001 to 0.600 mg/ml and scanned for fluorescence peaks from 306 to 346 nm 
as shown in Figure 3(A). A plot of fluorescence intensity ratio I336/I330 against 
the DSPE-PEG2000/TPGS concentration was then used to determine the 
CMC. Figure 3(B) shows that the CMC of DSPE-PEG2000/TPGS was found 
to be 0.0218 ± 0.0006 mg/ml, which was 10 times lower than that of TPGS at 
0.200 mg/ml. This could be due to the presence of DSPE-PEG2000 that 
increased the hydrophobicity of the micelle thus resulting in greater stability. 
More experiments on time-dependent micelle stability could be studied to 




















Figure 3: (A) Excitation spectra of pyrene in DSPE-PEG2000/TPGS micelles 
and (B) plot of fluorescence intensity ratio I336/I330 from the excitation spectra 
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3.2 Drug release profile 
 
An effective drug carrier has to carry the encapsulated drug molecules for 
prolonged periods of time to allow drug accumulation via the EPR effect. This 
can be investigated by studying the drug release profile of the nanocarrier. 
Figure 4(A) and (B) show the drug release profiles of paclitaxel and vorinostat 
respectively in TPGS and DSPE-PEG2000/TPGS mixed micelles over a 
course of 169 days. A controlled drug release profile was observed for both 
micelles systems where an initial burst of 53.3% and 41.2% for the DSPE-
PEG2000/TPGS micelles and 57.7% and 50.6% for the TPGS micelles in the 
first 24 hours was encountered in P and S respectively. The faster release 
associated with TPGS micelles could be attributed to the lower molecular 
weight of TPGS, which resulted in a faster erosion of the polymeric matrix as 
well as the high content of TPGS and hence higher hydrophilicity, which 
allows enhanced water penetration into the micelles. The initial fast release of 
vorinostat and paclitaxel may also be attributed to some drugs remaining on 
the surface of the micelles as the micelles were not washed after formulation.  
 
It was also observed that P was released faster than S. The partition 
coefficient, logP, is an assessment of the relative hydrophobicity or 
lipophilicity of drugs. As P (logP = 3.96) is more hydrophobic than S (logP = 
1.88) due to a higher logP value and low hydrophobic behavior is generally 
associated with faster drug release, this phenomenon could be attributed to 
other factors relating to the diffusion path length or drug–micelle structure 
complex where more experiments could be done (Gill et al., 2012; Surapaneni, 
Das, & Das, 2012). The release half-life of S was also observed to be higher in 
DSPE-PEG2000/TPGS mixed micelles at 72 hours compared to that in TPGS 

























Figure 4: Drug release profile of (A) paclitaxel and (B) vorinostat in dual 
drug-loaded TPGS and DSPE-PEG2000/TPGS micelles over 169 hours. * p < 
0.05.  
 
3.3  in vitro studies 
3.3.1 Cellular uptake 
 
The micelles have to be internalized by the cancer cells where the anti-cancer 
drugs are released and subsequently exert their therapeutic effects. In this 
study, an investigation was conducted to compare the internalization or 
cellular uptake of the micelles to the free drugs. The fluorescent probe C6 was 
used as the drug in cellular uptake studies. The cellular uptake efficiency was 
analyzed quantitatively at concentrations of 2.5, 0.25 and 0.025 μg/ml and the 
results were illustrated in Figure 5(A) and (B) for an incubation period of 0.5 
















































































Figure 5: Quantitative cellular uptake efficiency of C6, C6-loaded TPGS 
micelles and C6-loaded DSPE-PEG2000/TPGS micelles at varying 
concentrations after a (A) 0.5-hour and (B) 2-hour incubation. * p < 0.05 
compared with C6.  !
In general, DSPE-PEG2000/TPGS micelles showed higher cellular uptake 
efficiency than TPGS micelles and C-6 free drugs. After a 0.5-hour incubation 
period, the mixed micelles indicated a 5.1-fold, 11.5-fold and 9.6-fold while 
TPGS micelles showed a 5.5-fold, 10.5-fold and 8.1-fold enhanced uptake 
than coumarin-6 free drugs for concentrations of 2.5, 0.25 and 0.025 μg/ml 
respectively. After a 2-hour incubation, the mixed micelles showed a 4.3-fold, 
14.0-fold and 7.1-fold while TPGS micelles indicated a 3.0-fold, 10.4-fold and 
5.9-fold enhanced uptake than C-6 free drugs for concentrations of 2.5, 0.25 
and 0.025 μg/ml respectively. The higher cellular uptake of DSPE-
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more negative zeta potential value since both micelle formulations have the 
same size. The extracellular pH of tumor cells is usually lower at 6.5 to 7.0; 
thus, under an acidic environment, particles with more negative surface 
charges i.e. DSPE-PEG2000/TPGS micelles are more easily internalized by 
the tumor cells.  
 
Results showed that higher concentration led to a higher cellular uptake but a 
decrease in efficiency. Furthermore, increase in incubation period led to 
enhanced cellular uptake efficiency. When the incubation period was 
increased from 0.5 hours to 2 hours, the cellular uptake efficiency of DSPE-
PEG2000/TPGS micelles was observed to increase from 12.1 ± 1.7% to 19.7 ± 
1.8%, 22.4 ± 0.3% to 51.0 ± 4.4%, and 34.3 ± 2.7% to 61.1 ± 4.7% while for 
TPGS micelles, it also exhibited an increase from 12.8 ± 1.4% to 13.6 ± 1.2%, 
20.4 ± 0.9 % to 37.9 ± 2.4 % and 29.0 ± 5.4 % to 51.2 ± 1.4 % for 
concentrations of 2.5, 0.25 and 0.025 μg/ml respectively. Due to the relative 
small size of the micelles, endocytosis is assumed to be the cellular uptake 
mechanism. The above results showed that DSPE-PEG2000/TPGS micelles 
are more efficient drug delivery carriers than TPGS micelles.  
 
Another investigation was carried out to show the qualitative cellular uptake 
of DSPE-PEG2000/TPGS loaded with C6. Figure 6 shows the confocal 
microscopic images of MDA-MB-231 cells after a 2-hour incubation with (A) 
negative control, (B) free C6 drugs and (C) C6 loaded DSPE-PEG2000/TPGS 
micelles. The nuclei were stained with DAPI in blue and the images were 
located on the first column; the f-actin were stained with phalloidin in red and 
located on the second column; the third column shows the fluorescence of the 
C6; and the last column shows the merged images. In DSPE-PEG2000/TPGS 
micelles, the image of green C6 is shown to coincide with the red f-actin, 
which suggested that the C6 loaded micelles are taken up and internalized 
within the cytoplasm. The fluorescence intensity of C6 was quantified using 
ImageJ and it was found out that the corrected total cell fluorescence (CTCF) 
in DSPE-PEG2000/TPGS micelles was 14.3-fold higher than that in free C6. 
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In free C6 as shown in row B, even though there was presence of some C6 
internalized, the fluorescence intensity was much lower.  
 
 
Figure 6: Cellular uptake and intracellular localization of (A) negative control, 
(B) C6 and (C) C6-loaded DSPE-PEG2000/TPGS micelles in MDA-MB-231 
cells after a 2-hour incubation !
3.3.2 MTT cell viability 
 
Combination therapy of paclitaxel and vorinostat in a single nanocarrier could 
achieve greater therapeutic effect by targeting different mechanisms of action. 
This often leads to lower drug doses required and hence, reduce the harmful 
side effects encountered by the patients. In this study, the cytotoxic effects of 
the various formulations either as free drugs or in DSPE-PEG2000/TPGS 
micelles formulations were investigated and the IC50 or the drug 
concentration required to inhibit 50% cell activity was determined for each 





formulation. Figure 7 shows the cytotoxic effect of (A) DSPE-
PEG2000/TPGS blank micelles and (B) the various formulations including P, 
S, P + S, Pmic, Smic, Pmic + Smic, (P + S)mic or blank micelles at the equivalent 
drug concentration of 25, 2.5, 0.25 and 0.025 μg/ml after incubation in MDA-
MB-231 cancer cells for 24 hours.  
 
The blank micelles were observed to have minimal cytotoxic effect to the 
cancer cells where the cell viabilities indicated 94.8 ± 5.4 %, 100.7 ± 9.2 %, 
101.2 ± 6.4 % and 98.7 ± 11.1 % for concentrations of 25, 2.5, 0.25 and 0.025 
μg/ml respectively.  In Figure 7(B), it is observed that increasing the drug 
concentration would have lower cell viability or higher cytotoxic activity. The 
cell viability data was then used to determine the IC50, which is presented in 
Table 3. 
 
The results from Table 3 showed that Pmic and Smic had an IC50 value of 1.132 
and 1.171 μg/ml respectively which was 1.25-fold and 2.43-fold more 
cytotoxic than their free drugs formulations. This suggested the advantages of 
using nanocarriers in drug delivery, which lowers the drug dosage required to 
achieve the same therapeutic effect. Paclitaxel and vorinostat were used in the 
weight ratio of 1 : 1  in combination therapy with three formulations.  
 
IC50 values were determined to be 3.071, 0.638 and 0.520 μg/ml for P + S, 
Pmic + Smic and (P + S)mic respectively which indicated that (P + S)mic was 5.91-
fold and 1.23-fold more cytotoxic than P + S and Pmic + Smic respectively. This 
also suggested that the nanocarrier system is more effective than the free drugs 
system and a single nanocarrier encapsulating both drugs is the most efficient 
system. (P + S)mic formulation also showed the lowest IC50 value. Other than 
being more cytotoxic, (P + S)mic is a more efficient drug delivery system than 
Pmic + Smic as it ensures better control of the therapeutic effects attained at the 
intended drug-drug ratio. It was also 2.72-fold, 5.48-fold, 2.18-fold and 2.25-
fold more cytotoxic than P, S, Pmic and Smic respectively which indicated that a 
combination chemotherapy, in particular in a nanocarrier system, is much 
more efficacious than single chemotherapy. This may be attributed to the 
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targeting of different signaling pathways using combination chemotherapy 
that proves to be useful in a heterogeneous disease such as TNBC.  
 
Data also showed that concurrent treatment of P + S had a higher IC50 value 
than either P or S alone, which may indicate the disadvantage of combination 
chemotherapy arising from the dissimilar pharmacokinetics of different drugs. 
However, when administered in a nanocarrier system such as (P + S)mic, the 
antagonistic effects encountered in P + S were reduced with improved 
pharmacokinetics as observed from the decrease in the IC50 value from 3.071 
to 0.520 μg/ml. This is possibly due to increased drug-drug interaction in a 
confined volume, which promotes complementary activities of the two 
chemotherapeutics. More studies could be done to investigate the mechanism 
of synergy.  Moreover, in a nanocarrier system, there is higher possibility that 
the nanocarrier reaches the targeted site of action at the designed drug ratio to 
exert its therapeutic effects. The drug ratio of the free drugs formulation may 
not be easily controlled and may reach the targeted site at a different drug ratio 
than was intended (Duong & Yung, 2013).  
 
Table 3: IC50 values of different formulations in MDA-MB-231 after a 24-
hour incubation 
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Figure 7: (A) Effect of concentration of the blank micelles on the viability of 
MDA-MB-231 cancer cells and (B) effect of concentration of the indicated 
formulations on the viability of MDA-MB-231 cancer cells after incubation 
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3.3.3 Cell cycle analysis 
 
Cell cycle analysis of the various formulations was studied using propidium 
iodide flow cytometry and analyzed by the ModFit LT software to gain a 
better understanding of the biochemical pathways that result in cell death. 
Figure 8(A) illustrates the cell cycle distribution after MDA-MB-231 cancer 
cells were treated with 0.25 μg/ml of the indicated formulations for 24 hours.  
 
The relative proportion of the cell cycle phases associated with each 
formulation is shown in Figure 8(B). The results suggested that the blank 
micelles did not cause cell cycle arrest as no significant changes in the cell 
cycle distribution was observed when compared to the negative control. 
Formulations that include paclitaxel such as P, Pmic, P + S, Pmic + Smic and (P + 
S)mic induced G2/M arrest with an accumulation of cells in the G2/M phase of 
more than 90%. This suggested that paclitaxel is very effective in inducing 
G2/M arrest when used as a free drug, in combination therapy or in nanocarrier 
system. However, the results also showed that encapsulating paclitaxel in 
micelles or combination chemotherapy with paclitaxel did not show any 
significant increase in the percentage of cells arrested in the G2/M phase 
compared to the paclitaxel free drug. This implied that although nanocarrier 
system or combination chemotherapy resulted in lower drug doses required, 
they had no effect on the cell cycle distribution. It was also observed that 
vorinostat-loaded micelles, Smic resulted in G1/S phase arrest, which could be 
mediated by the retinoblastoma pathway that targets cyclin-dependent kinase 
inhibitor p21 encoded by CDKN2A that is upregulated in TNBC.  In 
combination chemotherapy, results showed that the presence of vorinostat did 
not alter the cell arrest profile of paclitaxel since Pmic + Smic and (P + S)mic still 




Figure 8: (A) Cell cycle distribution by flow cytometry where MDA-MB-231 
cancer cells were treated with the indicated formulations for 24 hours and (B) 
the effect of the different formulations on MDA-MB-231 cancer cells arrested 
in the various cell cycle phases 
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3.3.4 Capase-3 activity  
 
Caspase-3 is a protein in the cysteine-aspartic acid protease (caspase) family 
where its activation plays a role in the execution-phase of apoptosis that 
causes the degradation of intracellular elements. It can occur via both the 
extrinsic death ligand and the intrinsic mitochondrial pathways. In this 
fluorescence-based assay, free fluorophore i.e. AFC is released and detected 
when the substrate DEVD-AFC is cleaved by the presence of activated 
caspase-3 (Porter & Jänicke, 1999).  The fluorescence of AFC from the 
indicated formulations were then compared with that of the control where 
there was an absence of activated caspase-3 to give the fold increase in 
caspase-3 activity as shown in Figure 9. It was observed that (P+S)mic 
exhibited the greatest fold-increase in caspase-3 activity i.e. 1.55-fold which 
implied that the combined micelle formulations led to the most significant 
apoptotic response. In general, micelle formulations yielded a greater fold-
increase in caspase-3 activity than the free drug formulations i.e. 1.35-fold 
increase in Pmic compared to 1.27-fold increase in P and 1.40-fold increase in 
Smic compared to 1.28-fold increase in S. This showed that by encapsulating 
drugs in micelles, higher apoptotic response due to caspase-3 activity could be 
achieved. Blank micelles with a 1.03-fold increase were observed to exhibit 
minimal apoptotic response.  
Figure 9: Fold-increase in caspase-3 activity of the indicated formulations 
compared with control in MDA-MB-231 cells after treatment for 24 hours. * p 
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3.3.5 Scratch wound-healing assay 
 
A scratch wound-healing assay was performed to investigate the effect of 
various drug formulations at an equivalent concentration of 0.01 μg/ml on the 
inhibition of cell migration after 24 hours. A scratch wound was created on the 
cell monolayer and in the absence of induced treatment, cells will move to 
close the gap. Figure 10(A) shows the images acquired at the start of the 
experiment as well as after 24 hours to compare the changes in the area of the 
wound gap. White dotted lines were drawn to illustrate the boundary of the 
gap for area calculation. The changes in the area at 0 hours and 24 hours were 
analyzed using ImageJ and used to calculate the percentage of wound closure 
by taking the quotient of the difference in wound gap area and the wound gap 
area at 0-hour which was illustrated in Figure 10(B). Blank micelles, S and 
Smic did not cause inhibition of cell migration with a 100% wound closure. It 
may be because they did not cause a significant effect on the growth factors at 
the concentration of 0.01 μg/ml. Comparing the two drugs individually, it was 
found that P had a much more significant effect on the blockage of cell 
migration than S which was probably due to the fact that P is also an inhibitor 
of angiogenesis that is involved in down-regulating vascular endothelial 
growth factor (VEGF) which is expressed in MDA-MB-231. When combined 
together especially in a micelle system, results showed that the (P+S)mic 
exhibited the most significant inhibition of cell migration compared to other 
formulations with a closure of the wound by 2.93 ± 0.01 % compared with 
100% in the untreated cells. This implied that the targeting of different 
mechanisms of action greatly enhanced the therapeutic potential and was thus 
more successful in preventing cell growth and metastasis. The wound closure 
was also more significant than that of Pmic + Smic (i.e. 15.97 ± 0.03 %). This 
implied that co-encapsulation of drugs within a single nanocarrier was more 
effective (i.e. 5.45-fold) in inhibiting growth factor production. (P+S)mic was 
also more successful in blocking cell invasion than single therapy system in 
both free drugs and micelle formulations i.e. 34.12-fold more effective than S 





Figure 10: (A) Cell migration in a scratch wound-healing assay where MDA-
MB-231 cancer cells were treated with the indicated formulations for 24 hours 
and (B) the effect of the different formulations on wound closure in 



























Both paclitaxel and vorinostat drugs were successfully loaded in DSPE-
PEG2000/TPGS mixed micelles for combination chemotherapy to achieve 
therapeutic effects in triple negative breast cancer cells. DSPE-
PEG2000/TPGS micelles were found to have a lower CMC value of 0.0218 ± 
0.0006 mg/ml and a more negative surface charge of -22.5 ± 2.9 mV than 
TPGS micelles, which contributed to its stability and enhanced cellular uptake 
efficiency. Drug encapsulation efficiencies of paclitaxel and vorinostat were 
also significantly higher in DSPE-PEG2000/TPGS micelles at 97.6 ± 0.3% 
and 99.5 ± 2.7% respectively. In vitro investigation was thus focused on 
comparing DSPE-PEG2000/TPGS micelles with other free drugs 
combinations. It was observed that the dual drug micelle system led to an 
improved pharmacokinetics than dual drug conventional chemotherapy when 
the IC50 value decreases from 3.071 to 0.520 μg/ml and overall, combinatory 
chemotherapy exhibited better anti-cancer effects than single drug treatment. 
Cell cycle analysis also showed that although vorinostat-loaded micelles 
induced G1/S arrest probably due to the retinoblastoma pathway, the cell cycle 
profile of paclitaxel was not altered and the dual drug mixed micelles still 
resulted in a significant and sustained cell arrest in the G2/M phase of 93%. 
Furthermore, the dual drug mixed micelles showed the most enhanced 
caspase-3 activity with a 1.55-fold increase compared to the control as well as 
an inhibition of cell migration with a wound closure by 2.93 ± 0.01% 
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